Key Studies in Lung Cancer: Independent Conference Coverage of the World Conference on Lung Cancer 2020
  • CME

January 28-31, 2021; Virtual Meeting
Review expert perspectives and insights on the most clinically relevant data in NSCLC, SCLC, and mesothelioma presented at the 2020 World Conference on Lung Cancer.
Shirish M. Gadgeel, MD
Nicolas Girard, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: March 31, 2021 Expiration: March 30, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with lung cancer and other thoracic malignancies
  • Identify subpopulations of patients with lung cancer and other thoracic malignancies most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with lung cancer and other thoracic malignancies
  • Consider how new trial findings might affect treatment of lung cancer and other thoracic malignancies in the future

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.
Janssen Pharmaceutica NV
Jazz Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Takeda Oncology

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Shirish M. Gadgeel, MD

Chief
Division of Hematology/Oncology
Department of Internal Medicine
Henry Ford Cancer Institute
Henry Ford Health System
Detroit, Michigan

Shirish M. Gadgeel, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, Takeda, and Xcovery; fees for non-CME/CE services from Merck Sharp & Dohme; and other financial or material support from AstraZeneca and Roche/Genentech.
Nicolas Girard, MD, PhD

Professor
Université Paris-Saclay
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Paris, France

Nicolas Girard, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Roche, Sanofi, and Teva, and funds for research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Roche.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Jill Sakai, PhD

Editorial Contributor

Jill Sakai, PhD, has no relevant conflicts of interest to report.
Kara Nyberg, PhD

Editorial Contributor

Kara Nyberg, PhD, has no relevant conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Kate Evans, ELS

Editorial Contributor

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with lung cancer.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 31, 2021, through March 30, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable powerpoint slideset with key takeways on the use of immune checkpoint inhibitors for resectable early-stage NSCLC, from Clinical Care Options (CCO)

Justin F. Gainor, MD
Program Director
Released: January 18, 2022

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in immunotherapy for early-stage NSCLC

Justin F. Gainor, MD
Program Director
Stephen V. Liu, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Drs Enriqueta Felip and Alexander Spira discuss the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC, from Clinical Care Options (CCO)

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 28, 2021 Expired: December 27, 2022

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2021 Expired: December 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings